COSENTYX 150 MG/ML S.C. 2 PREFILLED PENS

THE first AND only fully human il-17a antagonist. Secukinumab is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy- AND is indicated for the treatment of adult patients with active psoriatic arthritis - AND is indicated for the treatment of adult patients with active ankylosing spondylitis.